Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

And I predict that 2025 will be another momentous year for Summit. Summit already owned the license to market ivonescimab in ...

Verona Pharma reported a total of $36 million in net revenue for the fourth quarter of 2024, solely attributed to sales of Ohtuvayre (ensifentrine), its FDA-approved treatment for chronic ...

Verona Pharma reported a total of $36 million in net revenue for the fourth quarter of 2024, solely attributed to sales of Ohtuvayre (ensifentrine), its FDA-approved treatment for chronic obstructive ...

We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to ...

Firstly, as per the report of the third quarter of 2024, significant financial growth was seen as the net sales reported were $5.6 million, largely due to product sales of Ohtuvayre. Secondly, ...

The company bagged FDA approval for first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor Ohtuvayre (ensifentrine) last June, becoming the first inhaled product with a novel mechanism of ...

Likewise, Verona Pharma (VRNA) proved a strong contributor after it released strong quarterly earnings highlighting the strong launch of Ohtuvayre, its chronic obstructive pulmonary disease (COPD ...

Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectively More than 3,500 unique prescribers and over 16,000 prescriptions ...